Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (271-280 of 300) with videos related to

Pageof 30
Sort By:
Frontiers in Immunology|September 25, 2020
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionHilal Bhat, Gregor Zaun, Thamer A Hamdan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterMarcel Wiesweg, Saskia Ting, Henning Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Nature Communications|March 2, 2017
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regressionHalime Kalkavan, Piyush Sharma, Stefan Kasper, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2024
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorRainer Hamacher, Kim M Pabst, Phyllis F Cheung, et al.
The Pharmacogenomics Journal|June 18, 2020
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
The Pharmacogenomics Journal|October 3, 2020
Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
The Lancet. Oncology|August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trialKim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
Pageof 30

Showing results (271-280 of 300) with videos related to

Sort By:
Pageof 30
Frontiers in Immunology|September 25, 2020
Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma RegressionHilal Bhat, Gregor Zaun, Thamer A Hamdan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterMarcel Wiesweg, Saskia Ting, Henning Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Nature Communications|March 2, 2017
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regressionHalime Kalkavan, Piyush Sharma, Stefan Kasper, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 4, 2024
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorRainer Hamacher, Kim M Pabst, Phyllis F Cheung, et al.
The Pharmacogenomics Journal|June 18, 2020
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
The Pharmacogenomics Journal|October 3, 2020
Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
The Lancet. Oncology|August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trialKim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
Pageof 30